Daptomycin
KL Tedesco, MJ Rybak - Pharmacotherapy: The Journal of …, 2004 - Wiley Online Library
… Tedesco KL, Rybak MJ. In vitro activities of daptomycin, arbekacin and tigecycline (GAR-936)
against several clinical glycopeptide-intermediate Staphylococcus species [abstr]. …
against several clinical glycopeptide-intermediate Staphylococcus species [abstr]. …
Diffusion tensor imaging, white matter lesions, the corpus callosum, and gait in the elderly
RA Bhadelia, LL Price, KL Tedesco, T Scott, WQ Qiu… - Stroke, 2009 - Am Heart Assoc
Background and Purpose— Gait impairment is common in the elderly, especially those with
stroke and white matter hyperintensities on conventional brain MRI. Diffusion tensor imaging …
stroke and white matter hyperintensities on conventional brain MRI. Diffusion tensor imaging …
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization–positive metastatic breast cancer: a multi …
Purpose To determine the efficacy and safety of weekly docetaxel and trastuzumab as first-
or second-line therapy in women with HER-2–overexpressing metastatic breast cancer and …
or second-line therapy in women with HER-2–overexpressing metastatic breast cancer and …
Increased cochlear fluid-attenuated inversion recovery signal in patients with vestibular schwannoma
RA Bhadelia, KL Tedesco, S Hwang… - American journal …, 2008 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Elevated protein levels have been reported in perilymph of
patients with vestibular schwannoma. Fluid-attenuated inversion recovery (FLAIR) imaging …
patients with vestibular schwannoma. Fluid-attenuated inversion recovery (FLAIR) imaging …
[HTML][HTML] Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine
therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human …
therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human …
The epidermal growth factor receptor as a target for gastrointestinal cancer therapy
KL Tedesco, AC Lockhart, JD Berlin - Current treatment options in …, 2004 - Springer
Opinion statement The epidermal growth factor receptor (EGFR) is a member of the family of
transmem-brane protein kinase receptors known as the erbB or HER receptor family. When …
transmem-brane protein kinase receptors known as the erbB or HER receptor family. When …
An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer
…, G Bhat, MR Choi, G Reddy, KL Tedesco… - Cancer …, 2018 - Wiley Online Library
This randomized, open‐label, active‐controlled study investigated the safety and efficacy of
three doses of Rolontis (eflapegrastim), a novel, long‐acting myeloid growth factor, versus …
three doses of Rolontis (eflapegrastim), a novel, long‐acting myeloid growth factor, versus …
Prostate cancer early detection practices among men with a family history of disease
…, PA Peyser, SB Gruber, SE Bonnell, KL Tedesco… - Urology, 2003 - Elsevier
OBJECTIVES: Genetic studies of familial prostate cancer, which is often asymptomatic until
advanced stages, rely on correct designation of affection status. In this pilot study, we set out …
advanced stages, rely on correct designation of affection status. In this pilot study, we set out …
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer
…, PV Acevedo, CA Encarnacion, KL Tedesco… - Breast cancer research …, 2009 - Springer
Cisplatin and carboplatin have antitumor activity in breast cancer. Satraplatin, an orally
bioavailable platinum analog, offers a potential alternative to intravenous chemotherapy. We …
bioavailable platinum analog, offers a potential alternative to intravenous chemotherapy. We …
Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results …
Introduction: Only half of hormone receptor positive (HR+) metastatic breast cancer (MBC)
patients (pts) benefit from endocrine therapy (ET). Circulating tumor cells (CTC) are prognostic …
patients (pts) benefit from endocrine therapy (ET). Circulating tumor cells (CTC) are prognostic …